Get the Stockscreener App
203.49
1.37%
2.76
After Hours:
204.93
1.44
+0.71%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca Plc stock is traded at $203.49, with a volume of 2.05M.
It is up +1.37% in the last 24 hours and down -0.12% over the past month.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
See More
Previous Close:
$200.73
Open:
$199.78
24h Volume:
2.05M
Relative Volume:
0.47
Market Cap:
$315.58B
Revenue:
$58.80B
Net Income/Loss:
$10.24B
P/E Ratio:
62.06
EPS:
3.2788
Net Cash Flow:
$8.98B
1W Performance:
+10.95%
1M Performance:
-0.12%
6M Performance:
+143.26%
1Y Performance:
+181.76%
1-Day Range:
$199.23
$204.34
1-Week Range:
$187.95
$204.34
52-Week Range:
$61.24
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Name
Astrazeneca Plc
Sector
Industry
Phone
-
Address
-
Compare AZN vs LLY, JNJ, ABBV, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
203.49 | 315.58B | 58.80B | 10.24B | 8.98B | 3.2788 |
LLY
Lilly Eli Co
|
935.58 | 835.81B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
243.04 | 585.39B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
208.84 | 369.39B | 61.16B | 4.19B | 17.82B | 2.3614 |
MRK
Merck Co Inc
|
120.87 | 298.84B | 64.93B | 18.26B | 12.36B | 7.2751 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Buy |
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca Plc Stock (AZN) Latest News
AstraZeneca stock gains 1.77% as bullish technicals and positive trial results fuel buying - Traders Union
AstraZeneca PLC stock: Positive liver cancer trial results spark investor interest - AD HOC NEWS
AstraZeneca (AZN) Faces New Tariff Challenges Amid U.S. Import D - GuruFocus
AstraZeneca’s New Cancer Combo Trial Signals Steady Progress in Antibody Drug Conjugates - TipRanks
AstraZeneca climbs Thursday, outperforms market - MarketWatch
Q1 2026 Dividend Check-In: Highest Quarterly Hike Percentage Since 2019 - Investing.com
Guggenheim Lifts PT on AstraZeneca PLC (AZN) to 16,500 GBp From 16,000 GBp - Insider Monkey
AstraZeneca reports positive phase III results for Imfinzi and Imjudo in liver cancer - Investing.com
AstraZeneca (NYSE: AZN) liver cancer combo boosts PFS in Phase III - stocktitan.net
AstraZeneca PLCImfinzi+Imjudo improves PFS in early liver cancer - Research Tree
AstraZeneca’s Liver Cancer Treatment Shows Promise in Phase III Trial - AskTraders
AstraZeneca's liver cancer therapy combo slows disease progression in late-stage trial - Reuters
AstraZeneca (AZN) Sees Success in EMERALD-3 Trial for Liver Canc - GuruFocus
ASTRAZENECA : Buy rating from JP Morgan - MarketScreener
Pictet North America Advisors SA Has $8.54 Million Stock Holdings in Astrazeneca Plc $AZN - MarketBeat
Astrazeneca plc Announces Positive High-Level Results from the Emerald-3 Phase III Trial - MarketScreener
AstraZeneca hails encouraging data for liver cancer drug regimen - London South East
AstraZeneca upbeat on results of liver cancer treatment trial - sharecast.com
AstraZeneca Says Liver Cancer Drug Combination Extends Progression-Free Survival in Phase 3 Trial - MarketScreener
AstraZeneca Reports Positive Phase III EMERALD-3 Results In Unresectable Liver Cancer - directorstalkinterviews.com
Deutsche Bank Maintains Sell on AstraZeneca (AZN) - Insider Monkey
Nordic Stocks in North AmericaAstraZeneca Gains 1.8 Percent - MarketScreener
Cowen Maintains Buy on AstraZeneca PLC (AZN) March 18, 2026 - Meyka
AstraZeneca PLC Stock: Institutional Confidence Builds as Voting Rights Update Signals Stability for - AD HOC NEWS
AstraZeneca PLC Stock Gains Momentum on Positive Tozorakimab Phase 3 Data for COPD Treatment - AD HOC NEWS
Strong clinical milestones drive AstraZeneca stock higher despite mixed momentum readings - Traders Union
AstraZeneca updates total voting rights following admission of new shares - Investing.com
AstraZeneca (NYSE: AZN) updates voting rights and admits new shares - Stock Titan
AstraZeneca PLC Stock (AZN) Moved Up by 3.43% on Apr 1: Facts Behind the Movement - TradingKey
US bank sees AstraZeneca HPP drug data as supportive of $2.6bn forecast with upside to $4.4bn despite mixed trial results - Proactive financial news
AstraZeneca reports positive data from Phase III trial of efzimfotase alfa - Clinical Trials Arena
Moody Lynn & Lieberson LLC Increases Holdings in Astrazeneca Plc $AZN - MarketBeat
Morgan Stanley sees double-digit EPS growth for AstraZeneca PLC (AZN) - MSN
What's Going On With AstraZeneca Stock Tuesday?AstraZeneca (NYSE:AZN) - Benzinga
AstraZeneca PLC Stock (AZN) Opened Up by 3.38% on Mar 31: Drivers Behind the Movement - tradingkey.com
AstraZeneca’s ALXN1850 On Blockbuster Trajectory Despite Mixed Phase III Results - Citeline News & Insights
Astrazeneca reports positive phase III results for efzimfotase alfa in hypophosphatasia - Investing.com
ASTRAZENECA : Buy rating from Barclays - MarketScreener
AstraZeneca (AZN) Reports Positive Results from HPP Clinical Tri - GuruFocus
[6-K] ASTRAZENECA PLC Current Report (Foreign Issuer) | AZN SEC FilingForm 6-K - Stock Titan
AstraZeneca PLC (AZN) Stock Price, Trades & News - GuruFocus
ASTRAZENECA : JP Morgan maintains a Buy rating - MarketScreener
Eyes on Asia: Otsuka, Biogen, AstraZeneca - BioXconomy
ASTRAZENECA : Buy rating from Jefferies - MarketScreener
AstraZeneca says hypophosphatasia replacement enzyme trials positive - London South East
Boston Common Asset Management LLC Increases Stock Holdings in Astrazeneca Plc $AZN - MarketBeat
AstraZeneca drug for rare bone disease shows positive trial results - Sharecast.com
ASTRAZENECA : Barclays remains its Buy rating - MarketScreener
Astrazeneca Plc $AZN Shares Bought by Allspring Global Investments Holdings LLC - MarketBeat
AstraZeneca PLC Stock: Positive Tozorakimab COPD Trial Results Drive Shares Higher Amid Strong Pipel - AD HOC NEWS
Efzimfotase alfa demonstrated positive results from global Phase III clinical programme in hypophosphatasia - AstraZeneca
Astrazeneca Plc Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.02%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):